Treatment of complex regional pain syndrome type I with neridronate: A randomized, double-blind, placebo-controlled study

Rheumatology (United Kingdom)

Volumn 52, Issue 3, 2013, Pages 534-542

  Varenna, Massimo ^a   Adami, Silvano ^b   Rossini, Maurizio ^b   Gatti, Davide ^b   Idolazzi, Luca ^b   Zucchi, Francesca ^a   Malavolta, Nazzarena ^c   Sinigaglia, Luigi ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Malpighi Hospital   (Italy)

Author keywords

Algodystrophic syndrome; Bisphosphonates; Complex regional pain syndrome type I; Neridronate; Randomized clinical trial

Indexed keywords

NERIDRONIC ACID; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; REFLEX SYMPATHETIC DYSTROPHY; TREATMENT OUTCOME;

EID: 84874086561     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes312     Document Type: Article

References (30)

1. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, 2nd edn. Seattle: IASP Press, 1994.
2. de Mos M, de Bruijn AG, Huygen FJ et al. The incidence of complex regional pain syndrome: a population-based study. Pain 2007;129:12-20.
3. Harden RN, Bruehl S, Stanton-Hicks M et al. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med 2007;8:326-31.
4. Harden RN, Bruehl S, Perez RS et al. Validation of proposed diagnostic criteria (the 'Budapest Criteria') for complex regional pain syndrome. Pain 2010;150:268-74.
5. Tran de QH, Duong S, Bertini P et al. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth 2010;57:149-66.
6. Perez RS, Zollinger PE, Dijkstra PU et al. Evidence based guidelines for complex regional pain syndrome type 1. BMC Neurol 2010;31:10-20.
7. Brunner F, Schmid A, Kissling R et al. Biphosphonates for the therapy of complex regional pain syndrome I-systematic review. Eur J Pain 2009;13:17-21.
8. Adami S, Bevilacqua M, Broggini M et al. Short-term intravenous therapy with neridronate in Paget's disease. Clin Exp Rheumatol 2002;20:55-8.
9. Adami S, Gatti D, Colapietro F et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18:126-30.
10. Huskisson EC. Measurement of pain. Lancet 1974;2: 1127-31.
11. Cappello ZJ, Kasdan ML, Louis DS. Meta-analysis of the imaging techniques for the diagnosis of complex regional pain syndrome type I. J Hand Surg Am 2012;37: 288-96.
12. Forouzanfar T, Weber WE, Kemler M et al. What is a meaningful pain reduction in patients with complex regional pain syndrome type 1? Clin J Pain 2003;19: 281-5.
13. Adami S, Fossaluzza V, Gatti D et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997;56:201-4.
14. Varenna M, Zucchi F, Ghiringhelli D et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000;27:1477-83.
15. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphoshonate administration. Calcif Tissue Int 1987;41:326-33.
16. Ochoa JL. Pain mechanisms in neuropathy. Curr Opin Neurol 1994;7:407-14.
17. Breuer B, Pappagallo M, Ongseng F et al. An open-label pilot trial of ibandronate for complex regional pain syndrome. Clin J Pain 2008;24:685-9.
18. Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004;5:276-80.
19. Manicourt DH, Brasseur JP, Boutsen Y et al. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004;50:3690-7.
20. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
21. Varenna M, Casari S, Zucchi F et al. Neridronato endovenoso nel trattamento delle sindrome algodistrofica. In: IV National Congress of Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases, Palermo, 2004. Abstract 51.
22. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.
23. Kozin F. Reflex sympathetic dystrophy syndrome. Curr Opin Rheumatol 1994;6:210-6.
24. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001;57:2179-84.
25. Leitha T, Korpan M, Staudenherz A et al. Five phase bone scintigraphy supports the pathophysiological concept of a subclinical inflammatory process in reflex sympathetic dystrophy. Q J Nucl Med 1996;40:188-93.
26. Birklein F, Weber M, Neundörfer B. Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia? Neurology 2000;55:1213-5.
27. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001;57:2179-84.
28. Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008;437:199-202.
29. Moreau MF, Guillet C, Massin P et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 2007;73:718-23.
30. Sabsovich I, Wei T, Guo TZ et al. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008;138:47-60.